Unum shares ricochet lower as premier drug slams into its second safety crisis, FDA slaps another hold on PhI
Unum Therapeutics’ ailing shares $UMRX took a crippling hit after the market closed on Tuesday as executives revealed that the FDA had slapped a clinical hold on their premier Phase I drug after a patient in the safety cohort recently experienced serious adverse events that included grade 3 neurotoxicity and cytomegalovirus infection as well as grade 4 respiratory distress.
And this wasn’t the first time Unum’s run into the same set of severe safety issues with this therapy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.